Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research suggests a biomimetic hematoma scaffold may enable ultra-low-dose BMP-2 to outperform standard collagen sponge delivery in large bone defect repair.
By Peptide Association Research Team
New research suggests elamipretide (SS-31) may support recovery after spinal cord injury by preserving mitochondrial function and reducing cell death in animal models.
By Peptide Association Research Team
New research explores how copper peptide GHK-Cu combined with glucose oxidase may support diabetic wound healing through cascade catalysis. Learn what the study found.
By Peptide Association Research Team
A 2026 study found BPC-157 and hybrid analogs may inhibit acetylcholinesterase, a key enzyme in Alzheimer's disease. Learn what the research means.
By Peptide Association Research Team
A 2026 rat study suggests BPC 157 may reduce oxidative stress and muscle damage from ischemia-reperfusion injury. Learn what the research found.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Read the findings and what they mean for research.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's development barriers, formulation challenges, and why human clinical data remains critically limited.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Learn what the research shows and its limitations.
By Peptide Association Research Team
New rat study suggests BPC 157 may reduce oxidative stress and tissue damage from ischemia-reperfusion injury. Learn what the research shows and its limitations.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines BPC-157's biopharmaceutical challenges, pharmacokinetic gaps, and the barriers standing between preclinical promise and human trials.
By Peptide Association Research Team
A 2026 rat study found BPC 157 may reduce oxidative stress and apoptosis in lower limb ischemia-reperfusion injury. Learn what the research suggests.
By Peptide Association Research Team
A 2026 review in Pharmaceutics examines why BPC-157 lacks approved formulations, validated dosing, and completed Phase II trials despite 30+ years of preclinical data.
By Peptide Association Research Team
A 2026 rat study suggests BPC 157 may protect against ischemia-reperfusion injury by reducing oxidative stress, inflammation, and cell death. Learn what the research shows.
By Peptide Association Research Team
A 2026 review in JBJS Reviews examines the evidence, safety, and antidoping implications of injectable peptides used in sports medicine and orthopaedics.
By Peptide Association Research Team
A 2026 structured review examines injectable peptides for musculoskeletal recovery. Learn what the evidence, safety data, and antidoping rules mean for athletes.
By Peptide Association Research Team
A 2026 study found BPC 157 may relax human arterial tissue via nitric oxide pathways. Learn what the research suggests and what patients should know.
By Peptide Association Research Team
A 2026 study suggests BPC 157 may relax human arterial tissue via nitric oxide signaling. Learn what the research found and what it means for vascular health.
By Peptide Association Research Team
A 2026 study found BPC 157 may promote vasorelaxation in human arterial tissue via nitric oxide pathways. Learn what the research suggests.
By Peptide Association Research Team
New research examines safety profiles of approved and unapproved peptide therapies for sports medicine, revealing gaps in human safety data for popular compounds.
By Peptide Association Research Team
New research examines safety and efficacy of approved vs. unapproved peptide therapies for musculoskeletal injuries and athletic performance.
By Peptide Association Research Team
New research examines safety and efficacy of approved vs unapproved peptide therapies for injury recovery and performance enhancement.
By Peptide Association Research Team
Recent study reveals tirzepatide achieved 22.7% weight loss at 52 weeks using telehealth protocol. Learn clinical implications for peptide therapy providers.
By Peptide Association Research Team
New research on SS-31 peptide reveals neuroprotective mechanisms in stroke models. Study findings on mitochondrial peptide therapy for brain health.
By Peptide Association Research Team
New research on retatrutide, a triple-agonist peptide therapy, demonstrates significant benefits for type 2 diabetes and obesity management in clinical studies.
By Peptide Association Research Team